All In Biotech

Drug Trial Radar · NCT02063685

Study to Evaluate the Efficacy of Response-adapted Strategy in Follicular Lymphoma

A Multicenter, Phase III, Randomized Study to Evaluate the Efficacy of Response-adapted Strategy to Define Maintenance After Standard Chemoimmunotherapy in Patients With Advanced-stage Follicular Lymphoma.

Last checked: Nov 20, 2026Latest source record: Jun 21, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 807 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

807

Actual

Start

Jul 2012

Primary completion

Dec 2021

Study completion Dec 2021

Sponsor

Lead sponsor
Fondazione Italiana Linfomi - ETSAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 14, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Recently, the availability of R has substantially changed therapeutic approach to FL patients, since its combination with chemotherapy has improved response rates, progression free survival (PFS) and overall survival (OS). Based on the results of recently completed randomized studies the standard treatment for patients with FL should consist of an initial therapy with R-CHOP combination followed by two-year maintenance with R. Although results of randomized trials confirmed that this approach results in an improved patients' outcome and made a step forward in the management of patients with FL, one important question that can be raised is if this approach is really needed for all patients with FL or if some of them could benefit from a reduced intensity treatment achieving the same results in terms of outcome and survival . This question is of particular interest for newly diagnosed patients for whom maintenance does not affect OS. More recent data demonstrated that the outcome of patients with FL can be further predicted by evaluating the quality of response to therapy studying minimal residual disease (MRD). This project addresses the objective of evaluating if combining clinical response assessed on FDG-PET scan and molecular response measured through MRD detection could permit to single out groups of patients at different risk of progression and to consequently modulate maintenance therapies, with the aim to provide clinicians a more rational use of the available diagnostic and therapeutic resources.

Conditions

  • Follicular Non-Hodgkin's Lymphoma

Interventions

  • R-CHOP or R-bendamustineDrug

    As induction therapy all patients will receive 6 courses of: Rituximab: 375 mg/m² day 1 iv Cyclophosphamide: 750 mg/m² day 1 iv Doxorubicin: 50 mg/m² day 1 iv Vincristine: 1.4 mg/m² day 1 iv (max dose 2mg) Prednisone: 100 mg day 1-5 os To allow administration of all drugs on the same day, Rituximab rapid infusion is permitted starting from cycle 2. Cycles are to be repeated every 21 days. or 6 courses of: Rituximab: 375 mg/m² day 1 iv Bendamustine: 90 mg/m² day 1 and 2 iv. To allow administration of all drugs on the same day, Rituximab rapid infusion is permitted starting from cycle 2. Cycles are to be repeated every 28 days.

  • ObservationDrug

    not maintenance therapy and followed-up with MRD monitoring.

  • Maintenance weekly x4Drug

    Four weekly doses of Rituximab (375 mg/m²). Rituximab could be repeated for MRD positive for a maximum of three courses

  • Ibritumomab Tiuxetan + MaintenanceDrug

    single dose of (90)Y Ibritumomab Tiuxetan (0.4 mCi/kg). Following RIT patients will continue maintenance with Rituximab (375 mg/m² every 2 months) for a total of 11 infusions.

  • Standard MaintenanceDrug

    Rituximab 375 mg/m² every 2 months for 2 years. Maintenance will have to be started no more than 12 weeks after the last induction chemoimmunotherapy infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PFSTime frame: 12/31/2019

Locations

48 sites in 1 country. Site status is shown where the registry gives one.

  • Ospedale Civile Ss. Antonio E Biagio Di Alessandria - Alessandria (Al)

    Alessandria, Italy

  • A.O. Universitaria Ospedali Riuniti - Ospedale Umberto I Di Ancona _

    Ancona, Italy

  • A.O. Universitaria Ospedale Consorziale Policlinico Di Bari

    Bari, Italy

  • A.O. Ospedale Degli Infermi

    Biella, Italy

  • A.O. Universitaria Policlinico S.Orsola-Malpighi Di Bologna

    Bologna, Italy

  • Pres.Ospedal.Spedali Civili Brescia

    Brescia, Italy

  • Stabilimento "Perrino" - Brindisi -

    Brindisi, Italy

  • Ospedale Armando Businco - Cagliari

    Cagliari, Italy

  • A.O. Universitaria Ospedale Vittorio Emanuele Di Catania

    Catania, Italy

  • Azienda Ospedaliera S. Croce E Carle Di Cuneo

    Cuneo, Italy

  • A.O. Universitaria Careggi Di Firenze

    Florence, Italy

  • A.O. Universitaria S. Martino Di Genova

    Genova, Italy

  • Ematologia Ospedale Vito Fazzi

    Lecce, Italy

  • Presidio Ospedaliero - Matera -

    Matera, Italy

  • Azienda Ospedaliera Papardo

    Messina, Italy

  • Irccs Ospedale Maggiore Policlinico Di Milano

    Milan, Italy

  • Ospedale Ca' Granda-Niguarda

    Milan, Italy

  • A.O. Universitaria Policlinico Di Modena

    Modena, Italy

  • Irccs Istituto Nazionale Tumori Fondazione Pascale

    Naples, Italy

  • A.O. Universitaria Maggiore Della Carita' Di Novara

    Novara, Italy

  • Ospedale San Francesco

    Nuoro, Italy

  • A.O. Universitaria Policlinico Giaccone Di Palermo

    Palermo, Italy

  • A.O. "V. Cervello"

    Palermo, Italy

  • A O Universitaria di Parma

    Parma, Italy

  • IRCCS Policlinico S. Matteo

    Pavia, Italy

  • Azienda Ospedaliera Di Perugia - Ospedale S. Maria Della Misericordia -

    Perugia, Italy

  • Ospedale Civile Spirito Santo

    Pescara, Italy

  • Ausl Di Piacenza

    Piacenza, Italy

  • A.O. Universitaria Pisana

    Pisa, Italy

  • Ospedale Bianchi - Melacrino - Morelli

    Reggio Calabria, Italy

  • Ausl Di Rimini

    Rimini, Italy

  • Universita' Degli Studi Di Roma 'La Sapienza'

    Roma, Italy

  • Casa sollievo della Sofferenza

    San Giovanni Rotondo, Italy

  • A.O. Universitaria Senese

    Siena, Italy

  • A.O. Universitaria S. Giovanni Battista-Molinette Di Torino

    Torino, Italy

  • Ospedale Ca Foncello

    Treviso, Italy

  • A.O.Cardinale Panico Ematologia e centro trapianti

    Tricase (LE), Italy

  • A.O. Universitaria S. Maria Della Misericordia Di Udine

    Udine, Italy

  • Ospedale Di Circolo E Fondazione Macchi

    Varese, Italy

  • Irst - Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori - Sede Di Meldola (Fc)

    Meldola, Forlì Cesena, Italy

Showing 40 of 48 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.